HepaLife announces appointment of Senior Medical Device and Healthcare Executive to the Board of Directors.

HepaLife’s patented PICM-19 cells demonstrate the ability to grow without becoming cancerous, survive in human plasma, and mimic important functions of the human liver -- functions crucial to integration into an artificial liver device.

Boston, MA – March 20, 2007 - HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) today announced the appointment of Mr. Javier Jimenez, a seasoned, senior medical device and healthcare executive with worldwide experience, to the Company’s Board of Directors.

“Mr. Jimenez brings a highly-accomplished executive background and much sought-after professional credentials to our team,” stated HepaLife President and CEO, Mr. Frank Menzler.  “I very much look forward to drawing on Javier’s expertise as we advance the commercial development of our cell-based technologies, which continue to produce promising outcomes for key applications, including avian influenza vaccine development, in vitro toxicology testing, and the first-of-its-kind artificial liver device.

“Our cell technologies really stand out against traditional industry products, especially in the area of artificial liver device development,” continued Mr. Menzler.  “HepaLife’s patented PICM-19 cells have shown a special capacity to grow at high densities and under conditions that would render other cell lines useless.  Most importantly, unlike others, our cells do not become cancerous after repeated growth, and they consistently imitate the behavior of the liver, which makes them ideally suited for incorporation into an artificial liver device.”

In ongoing research, scientists have demonstrated that the Company’s PICM-19 cells have unique characteristics distinct from other cells, and are able to successfully mimic the liver's response in several important ways.  Among other research outcomes, important liver specific activity levels in the PICM-19 cells were up to three times higher than those found in human-derived cell lines frequently used for similar applications.

This functionality is crucial, since according to researchers, the most vital component in an artificial liver device is not the mechanical hardware, but rather, it is the biological cells inside the device which are responsible for truly replicating and performing the functions of the human liver.

“It’s now more important than ever to build on our research success in the labs, all of which has transpired during the tenure of our outgoing Directors, Mr. Arian Soheili and Mr. Jasvir Kheleh,” continued Mr. Menzler.  “I want to thank them for their management guidance and tireless efforts during our early research and development phase, and welcome aboard Mr. Javier Jimenez who joins us as HepaLife moves its technologies through the development path and towards commercialization.

“I’m eager to leverage Javier’s 15-plus years of leadership experience in the commercial medical device and healthcare arenas,” concluded Mr. Frank Menzler.

Mr. Javier Jimenez brings more than 15 years of global experience, including executive-level management, sales, operations, finance, and mergers and acquisitions in the medical device and healthcare arena.

At GE Healthcare, a $15 billion unit of General Electric Company, Mr. Jimenez held several key finance and management positions in the United States and Latin America.  During his tenure at GE Healthcare, Mr. Jimenez led the $1.3 billion Americas GE Healthcare Information Technologies commercial operations group, and managed a team of analysts responsible for financial planning and analysis for the company’s $3 billion Americas Diagnostic Imaging Division.

At ABIOMED, Inc., developer of the world’s first self-contained artificial heart, Mr. Javier Jimenez served in numerous positions, most recently as Vice President, General Manager Europe, where he was responsible for key facets of the company’s operations in Europe, Middle East, and Africa. Mr. Jimenez held all profit and loss responsibilities for sales and marketing, clinical support, quality assurance, product development, regulatory affairs, finance, accounting and other key functions, totaling more than 30 direct and indirect reports.

As Vice President, Operations at ABIOMED, Inc., Mr. Javier Jimenez oversaw several areas, including finance, accounting, and mergers and acquisitions.  During this time, Mr. Jimenez led the company’s due diligence, negotiation, and successful closing of a $50 million acquisition.

In his role as acting Chief Financial Officer at ABIOMED, Inc., Mr. Javier Jimenez led the company’s interaction with external auditors and the Audit Committee of the Board of Directors, and effectively implemented Sarbanes-Oxley Section 404 internal controls.  Importantly, Mr. Javier Jimenez worked to successfully increase the company’s sell-side analyst coverage from zero to four firms.

Mr. Javier Jimenez earned his Bachelor and Masters degrees in Aeronautical Engineering from Universidad Politécnica in Madrid, Spain , and subsequently completed his MBA from Boston University.  He is also a certified Six Sigma Black Belt, an advanced management methodology.

ABOUT HEPALIFE TECHNOLOGIES, INC.

HepaLife Technologies, Inc. (OTCBB: HPLF - News; FWB: HL1) (WKN: 500625) is a biotechnology company focused on the identification and development of cell-based technologies and products.

Current cell-based technologies under development by HepaLife include 1) the first-of-its-kind artificial liver device, 2) proprietary in-vitro toxicology and pre-clinical drug testing platforms, and 3) novel cell-culture based vaccine production to protect against the spread of influenza viruses among humans, including potentially the high pathogenicity H5N1 virus.

For additional information, please visit www.hepalife.com.

To receive future press releases via email, please visit:

http://www.hepalife.com/investor-alerts.php

To view the full HTML text of this release, please visit:

http://www.hepalife.com/20070320-1.html.php

#      #      #      #

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that HepaLife will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.